Individualizing the selection of long-acting bronchodilator therapy for patients with COPD: considerations in primary care

References

• Ford ES. Trends in mortality from COPD among adults in the United States. Chest. 2015;148:962–970.
   PubMed Web of Science ®Google Scholar
• Ford ES. Hospital discharges, readmissions, and ED visits for COPD or bronchiectasis among US adults: findings from the nationwide inpatient sample 2001-2012 and Nationwide Emergency Department Sample 2006–2011. Chest. 2015;147:989–998.
   PubMed Web of Science ®Google Scholar
• Carlin BW. COPD and associated comorbidities: a review of current diagnosis and treatment. Postgrad Med. 2012;124:225–240.
   PubMed Web of Science ®Google Scholar
• Make B, Dutro MP, Paulose-Ram R, et al. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:1–9.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Kim K, Bacci ED, et al. Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population. NPJ Prim Care Respir Med. 2015;25:15024.
   PubMed Web of Science ®Google Scholar
• Ford ES, Mannino DM, Wheaton AG, et al. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988-1994 to 2007-2010. Chest. 2013;143:1395–1406.
   PubMed Web of Science ®Google Scholar
• The COPD Foundation. Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management; 2014 cited 2017 Mar 20. Available from: http://www.copdfoundation.org/About-Us/Press-Room/Press-Releases/ID/256/COPD-Foundation-Releases-Groundbreaking-COPE-Survey-Results-Low-Patient-Awareness-About-COPD-Exacerbations-Poses-Barrier-to-Effective-Management.aspx
   Google Scholar
• Salinas GD, Williamson JC, Kalhan R, et al. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis. 2011;6:171–179.
   PubMed Web of Science ®Google Scholar
• Perez X, Wisnivesky JP, Lurslurchachai L, et al. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106:374–381.
   PubMed Web of Science ®Google Scholar
• Barr RG, Celli BR, Mannino DM, et al. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med. 2009;122:348–355.
   PubMed Web of Science ®Google Scholar
• Harrison SL, Robertson N, Graham CD, et al. Can we identify patients with different illness schema following an acute exacerbation of COPD: a cluster analysis. Respir Med. 2014;108:319–328.
   PubMed Web of Science ®Google Scholar
• GOLD Guidlines Committee. Global initiative for chronic obstructive lung disease: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2017); cited 2017 Mar 20. Available from: www.goldcopd.org
   Google Scholar
• Ohar JA, Yawn BP, Ruppel GL, et al. A retrospective study of two populations to test a simple rule for spirometry. BMC Fam Pract. 2016;17:65.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Dalal AA, Johnson P, et al. A clinical study of COPD severity assessment by primary care physicians and their patients compared with spirometry. Am J Med. 2015;128:629–637.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–191.
   PubMed Web of Science ®Google Scholar
• Rennard S, Thomashow B, Crapo J, et al. Introducing the COPD foundation guide for diagnosis and management of COPD, recommendations of the COPD Foundation. Copd. 2013;10:378–389.
   PubMedGoogle Scholar
• Sharafkhaneh A, Altan AE, Colice GL, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014;108:1310–1320.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:1068–1079.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234.
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472–486.
   PubMed Web of Science ®Google Scholar
• Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Randomized, double-blind, dose-finding study for tiotropium when added to olodaterol, administered via the respimat(R) inhaler in patients with chronic obstructive pulmonary disease. Adv Ther. 2015;32:809–822.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Martinez FJ, Rodriguez-Roisin R, et al. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016;120:16–24.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48:1030–1039.
   PubMed Web of Science ®Google Scholar
• Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10:89–104.
   PubMed Web of Science ®Google Scholar
• Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105:930–938.
   PubMed Web of Science ®Google Scholar
• Souza ML, Meneghini AC, Ferraz E, et al. Knowledge of and technique for using inhalation devices among asthma patients and COPD patients. J Bras Pneumol. 2009;35:824–831.
   PubMed Web of Science ®Google Scholar
• Vanderman AJ, Moss JM, Bailey JC, et al. Inhaler misuse in an older adult population. Consult Pharm. 2015;30:92–100.
   PubMedGoogle Scholar
• Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol. 2004;93:439–446.
   PubMed Web of Science ®Google Scholar
• Coutinho AD, Lokhandwala T, Boggs RL, et al. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population. Int J Chron Obstruct Pulmon Dis. 2016;11:1223–1231.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127:335–371.
   PubMed Web of Science ®Google Scholar
• Wise RA, Acevedo RA, Anzueto AR, et al. Guiding principles for the use of nebulized long-acting beta2-agonists in patients with COPD: an expert panel consensus. Chronic Obstr Pulm Dis (Miami). 2017;4:7–20.
   Web of Science ®Google Scholar
• Quinet P, Young CA, Heritier F. The use of dry powder inhaler devices by elderly patients suffering from chronic obstructive pulmonary disease. Ann Phys Rehabil Med. 2010;53:69–76.
   PubMedGoogle Scholar
• Batterink J, Dahri K, Aulakh A, et al. Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease. Can J Hosp Pharm. 2012;65:111–118.
   PubMedGoogle Scholar
• Press VG, Arora VM, Shah LM, et al. Misuse of respiratory inhalers in hospitalized patients with asthma or COPD. J Gen Intern Med. 2011;26:635–642.
   PubMed Web of Science ®Google Scholar
• Cielen N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. Biomed Res Int. 2014;2014:965764.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Gifford AH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus(R) dry powder inhaler. J Aerosol Med Pulm Drug Deliv. 2013;26:174–179.
   PubMed Web of Science ®Google Scholar
• Jarvis S, Ind PW, Shiner RJ. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing. 2007;36:213–218.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Waterman LA, Ward J, et al. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate. J Aerosol Med Pulm Drug Deliv. 2014;27:103–109.
   PubMed Web of Science ®Google Scholar
• Singh B, Mielke MM, Parsaik AK, et al. A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment. JAMA Neurol. 2014;71:581–588.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Bonadiman L, Tognella S, et al. Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values. Int J Chron Obstruct Pulmon Dis. 2014;9:675–683.
   PubMed Web of Science ®Google Scholar
• Sachdev PS, Anstey KJ, Parslow RA, et al. Pulmonary function, cognitive impairment and brain atrophy in a middle-aged community sample. Dement Geriatr Cogn Disord. 2006;21:300–308.
   PubMed Web of Science ®Google Scholar
• Ortapamuk H, Naldoken S. Brain perfusion abnormalities in chronic obstructive pulmonary disease: comparison with cognitive impairment. Ann Nucl Med. 2006;20:99–106.
   PubMed Web of Science ®Google Scholar
• Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35:913–922.
   PubMed Web of Science ®Google Scholar
• Dodd JW, Chung AW, van den Broek MD, et al. Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med. 2012;186:240–245.
   PubMed Web of Science ®Google Scholar
• Dodd JW. Lung disease as a determinant of cognitive decline and dementia. Alzheimers Res Ther. 2015;7:32.
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;CD006829.
   PubMed Web of Science ®Google Scholar
• Oba Y, Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:469–479.
   PubMed Web of Science ®Google Scholar
• Banerji D, Mahler DA, Hanania NA. Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD. Expert Rev Respir Med. 2016;10:767–780.
   PubMed Web of Science ®Google Scholar
• Banerji D, Patalano F. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2016;110:79–80.
   PubMed Web of Science ®Google Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15–25.
   PubMed Web of Science ®Google Scholar
• Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;CD010844.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016;71:118–125.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–398.
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley P, Decramer M, et al. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. Chronic Obstr Pulm Dis (Miami). 2014;1:166–184.
   PubMedGoogle Scholar
• D’Urzo A, Donohue JF, Kardos P, et al. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015;16:1845–1860.
   PubMed Web of Science ®Google Scholar
• Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894–942.
   PubMed Web of Science ®Google Scholar
• Oba Y, Chandran AV, Devasahayam JV. Long-acting muscarinic antagonist versus inhaled corticosteroid when added to long-acting beta-agonist for COPD: a meta-analysis. COPD. 2016;13:677–685.
   PubMedGoogle Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Sampson T, Le HV, et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS One. 2014;9:e97149.
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Li H, Hinds D, et al. Risk of pneumonia with inhaled corticosteroid/long-acting beta2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:457–468.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD–a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203–223.
   PubMedGoogle Scholar
• Dalal AA, Patel J, D’Souza A, et al. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm. 2015;21:575–583.
   PubMed Web of Science ®Google Scholar
• O’Reilly JF, Williams AE, Holt K, et al. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J. 2006;15:346–353.
   PubMedGoogle Scholar
• Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418–1428.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Law M, Kowlessar B, et al. Impact of prolonged exacerbation recovery in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:943–950.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653–661.
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–963.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Vogelmeier C, Pieper MP, et al. Effect of tiotropium on COPD exacerbations: a systematic review. Respir Med. 2016;114:1–8.
   PubMed Web of Science ®Google Scholar
• Bollu V, Ernst FR, Karafilidis J, et al. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2013;8:631–639.
   PubMed Web of Science ®Google Scholar
• Bollu V, Ejzykowicz F, Rajagopalan K, et al. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ. 2013;16:1082–1088.
   PubMedGoogle Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866.
   PubMed Web of Science ®Google Scholar
• Diette GB, Dalal AA, D’Souza AO, et al. Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States. Int J Chron Obstruct Pulmon Dis. 2015;10:415–422.
   PubMed Web of Science ®Google Scholar
• Melzer AC, Feemster LM, Uman JE, et al. Missing potential opportunities to reduce repeat COPD exacerbations. J Gen Intern Med. 2013;28:652–659.
   PubMed Web of Science ®Google Scholar
• Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality. Copd. 2012;9:131–141.
   PubMedGoogle Scholar
• Tsai CL, Delclos GL, Camargo CA Jr. Emergency department case volume and patient outcomes in acute exacerbations of chronic obstructive pulmonary disease. Acad Emerg Med. 2012;19:656–663.
   PubMed Web of Science ®Google Scholar
• Han MK, Martinez CH, Au DH, et al. Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respir Med. 2016;4:473–526.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138.
   PubMed Web of Science ®Google Scholar